RxDoctor Payments DataLook up a doctor →

Alexander Fong, MD

Neurology · Merriam, KSNPI 1326201658

Payments from drug & device makers

$8,013in general payments, 2019–2025

Across 658 payments — averaging $12.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Teva Pharmaceuticals USA, Inc.$698
  • Novartis$423
  • Biogen$334
  • UCB, Inc.$248
  • Genentech USA, Inc.$235
  • plus $3K from 45 others

What the payments were for

  • Speaking & faculty fees$611%
  • Food & beverage$7,92399%
  • Education$300%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,013 in reported general payments places this provider in the 70th percentile of 131 neurology providers in Kansas.

See all neurology providers in Kansas

Medicare billing

Part B allowed, 2024
$177,199
Medicare patients
426
Services billed
8,862

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4615$169,838
MayzentSiponimod13$130,992
BotoxOnabotulinumtoxina62$90,660
CopaxoneGlatiramer Acetate13$74,599
XcopriCenobamate15$29,023
UbrelvyUbrogepant20$26,646
Aimovig AutoinjectorErenumab-Aooe25$25,670
QuliptaAtogepant19$22,578
Emgality PenGalcanezumab-Gnlm31$22,017
Levetiracetam264$9,039
NayzilamMidazolam11$7,490
Lacosamide91$6,811
Dalfampridine ErDalfampridine13$6,146
Carbidopa-LevodopaCarbidopa/Levodopa211$5,868
Memantine Hcl179$4,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$2,976$139,884101 claims
NovartisMayzent$423$130,99213 claims
Teva Pharmaceuticals USA, Inc.Copaxone$698$74,59913 claims
SK Life Science, Inc.Xcopri$44$29,02315 claims
UCB, Inc.Nayzilam$248$7,49011 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide, Mycophenolate Mofetil$111$3,32733 claims
Upsher-smith Laboratories LLCTopiramate$14$65952 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 131 neurology providers in Kansas.

Other neurology in Merriam

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →